This result signifies that MT-RNR1 variants associated with aminoglycoside-induced hearing loss were not detected in this patient. Based on this genotype result, no change in aminoglycoside therapy is warranted. It should be noted that this result does not absolutely rule out the possibility of the patient developing ototoxicity with aminoglycoside use.